Marvaso Giulia, Vischioni Barbara, Jereczek-Fossa Barbara Alicja, Ciardo Delia, Fossati Piero, Giandini Tommaso, Morlino Sara, Carrara Mauro, Romanelli Paola, Russi Elvio, Valvo Francesca, Valdagni Riccardo, Orecchia Roberto
Department of Radiotherapy, IEO-European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.
Clinical Division, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
Radiol Med. 2017 Feb;122(2):140-145. doi: 10.1007/s11547-016-0699-1. Epub 2016 Oct 21.
Hadrontherapy has been in constant progress in the past decades. Due to the increasing interest in this field and the spreading of the technique in Italy and worldwide, the Italian Society of Radiation Oncology surveyed (by an online survey) its members regarding their perception of hadrontherapy. The survey outline addressed different items all related to hadrontherapy, such as: demographics (3 items), personal knowledge (5 items), actual use in clinical practice (5 items), and future perspectives and development (5 items). The survey was filled in by 224 radiation oncologists (RO). Among them, 74.6 % were RO with more than 5 years of clinical practice, and only 10.4 % RO in training. Median age was 46 years (range 27-77). 32.24 % admitted average knowledge about heavy particles radiobiology rationale and 32.42 % about the ongoing particle therapy clinical trials. Radioresistant tumors are perceived as-principal indications for carbon ions in 39.3 % of responders, and pediatric malignancies for protons in 37 %. Re-irradiation is highly recommended for 52.2 %. Strikingly, 38.8 % of participating ROs reported that, in the daily clinical practice, approximately less than 1 out of 10 patients asks to be referred for hadrontherapy. On the other side, 35.7 % claimed need for at least 3 up to 5 particle therapy centers in Italy. Overall, the results of the present survey highlight the interest of the Italian RO community for particle therapy among the other radiotherapy technique. Analysis of our results might picture the clinical attitude of the RO community towards hadrontherapy in Italy, and help in promoting targeted initiatives to spread clinical results and knowledge about technical innovations in this field.
在过去几十年中,强子治疗一直在不断发展。由于对该领域的兴趣日益浓厚,以及该技术在意大利和全球范围内的推广,意大利放射肿瘤学会通过在线调查对其成员关于强子治疗的看法进行了调查。调查问卷大纲涉及与强子治疗相关的不同项目,例如:人口统计学(3项)、个人知识(5项)、临床实践中的实际应用(5项)以及未来前景和发展(5项)。共有224名放射肿瘤学家填写了该调查问卷。其中,74.6%是具有超过5年临床实践经验的放射肿瘤学家,只有10.4%是正在接受培训的放射肿瘤学家。年龄中位数为46岁(范围为27 - 77岁)。32.24%的受访者表示对重粒子放射生物学原理了解一般,32.42%的受访者对正在进行的粒子治疗临床试验了解一般。39.3%的受访者认为抗辐射肿瘤是碳离子治疗的主要适应症,37%的受访者认为质子治疗的主要适应症是儿童恶性肿瘤。52.2%的受访者强烈推荐再次放疗。令人惊讶的是,38.8%的参与调查的放射肿瘤学家报告称,在日常临床实践中,每10名患者中大约不到1人要求转诊接受强子治疗。另一方面,35.7%的受访者声称意大利至少需要3至5个粒子治疗中心。总体而言,本次调查结果凸显了意大利放射肿瘤学界对粒子治疗相对于其他放射治疗技术的兴趣。对我们结果的分析可能描绘出意大利放射肿瘤学界对强子治疗的临床态度,并有助于推动有针对性的举措,以传播该领域的临床结果和技术创新知识。